Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. develops monoclonal and bispecific DR3-blocking antibodies for inflammatory and immune-mediated diseases. The company’s news centers on SL-325, a Death Receptor 3 antibody targeting the DR3/TL1A pathway, with emphasis on clinical development in inflammatory bowel disease and related immune-mediated conditions.
Recurring updates also cover quarterly financial results, cash and capital-structure disclosures, investor conference participation, inducement equity awards, and governance matters tied to Shattuck’s Nasdaq-listed common stock.
Shattuck Labs (NASDAQ: STTK) reported second quarter 2026 results and pipeline progress, highlighted by Phase 1 data for lead DR3 blocker SL-325 showing a favorable safety profile, 3.7% antidrug antibody incidence, durable TL1A/DR3 blockade for over three months at ≥1 mg/kg, and no DR3 agonism.
The RECEPTIVE-CD1 randomized, double-blind, placebo-controlled Phase 2b trial in ~232 Crohn’s disease patients is expected to start in Q3 2026, with 12-week endoscopic response data in H1 2028. Bispecific DR3 x IL-23R candidate SL-846 is in GLP toxicology, with a Phase 1 trial and initial data planned for 2027. Cash, cash equivalents and short-term investments rose to $208.3 million at June 30, 2026, helped by an $86.2 million public offering and $57.1 million warrant exercises, and are expected to fund operations into 2029. Q2 2026 net loss was $15.2 million with no revenue.
Shattuck Labs (NASDAQ: STTK) priced a public offering of 10,879,376 common shares at $4.00 and pre-funded warrants for up to 7,870,624 shares at $3.9999 each. Gross proceeds are expected to be about $75 million before expenses. Closing is expected on June 11, 2026, with underwriters holding a 30-day option to buy up to 2,812,500 additional shares.
Shattuck Labs (NASDAQ: STTK) commenced a proposed public offering of common stock and, for certain investors, pre-funded warrants to purchase common shares. All securities will be offered by Shattuck.
Underwriters are expected to receive a 30-day option to buy up to an additional 15% of shares. The offering’s completion, size and terms remain subject to market and other conditions under an effective SEC registration.
Shattuck Labs (NASDAQ: STTK) reported that holders have exercised or given notices to exercise approximately 50.6 million common stock warrants, about 96% of warrants issued in the August 4, 2025 private placement. This is expected to generate roughly $54.9 million in gross proceeds, including $5.6 million received by March 31, 2026 and an additional $49.3 million anticipated. Combined with $90.4 million in cash, cash equivalents and short-term investments as of March 31, 2026, Shattuck expects to fund operations into 2029, based on current plans.
Shattuck Labs (NASDAQ: STTK) reported Phase 1 results for DR3-blocking antibody SL-325 in 72 healthy volunteers. Only 3.7% (2/54) developed low‑titer antidrug antibodies, with no impact on PK or receptor occupancy. Complete DR3 occupancy occurred at ≥0.1 mg/kg, with TL1A blockade lasting over 10 weeks.
SL-325 showed no DR3 agonism, no cytokine changes, and only Grade 1 treatment-related adverse events, with no serious events. A Phase 2b Crohn’s disease trial is expected to start in Q3 2026, and bispecific candidate SL-846 is progressing through IND-enabling toxicology.
Shattuck Labs (NASDAQ: STTK) will host an investor call and webcast on June 8, 2026 at 8:00 a.m. ET to present comprehensive Phase 1 clinical data for SL-325, a potentially first-in-class DR3 blocking antibody, and provide a pipeline update.
The event will feature Shattuck’s management team and include a Q&A session, with live and replay access via the company’s website.
Shattuck Labs (NASDAQ: STTK) reported Q1 2026 results and program milestones on May 7, 2026. Cash and short-term investments were $90.4M as of March 31, 2026, up from $60.9M a year earlier. Q1 net loss was $14.8M (or $0.13 per share). Enrollment in the Phase 1 trial of SL-325 is complete; full Phase 1 data are expected in Q2 2026 and a Phase 2 trial in Crohn’s disease is planned for Q3 2026. The lead bispecific antibody has entered IND-enabling activities. Cash runway is expected into 2029 assuming full exercise of outstanding warrants.
Shattuck Labs (NASDAQ: STTK) reported Q4 and full-year 2025 results and program updates. As of Dec 31, 2025 cash and short-term investments were $78.1M; preliminary Feb 28, 2026 cash was $94.5M after $21.4M ATM sales. Q4 R&D fell to $9.1M (Q4 2024: $15.4M); full‑year R&D was $35.3M (2024: $67.2M). Net loss improved to $48.8M for 2025 (2024: $75.4M).
Clinical: Phase 1 SL-325 trial is nearly complete with data expected in Q2 2026; Phase 2 in Crohn’s disease is planned to begin in Q3 2026, subject to positive Phase 1 data and regulatory alignment. Lead bispecific entered IND-enabling activities.
Shattuck Labs (NASDAQ: STTK) announced CEO Taylor Schreiber, M.D., Ph.D., will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 9:10 AM ET in Boston and hold one-on-one meetings at the Leerink Partners 2026 Global Health Care Conference March 10-11 in Miami.
Live audio webcasts will be available via the company's Investor Relations website, with replay accessible for about 30 days after each presentation.
Shattuck Labs (NASDAQ: STTK) will present a prerecorded fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026 at 2:00 PM ET. Presenters include Taylor Schreiber, M.D., Ph.D. (CEO), Andrew R. Neill (CFO), and Michael Choi, M.D. (VP Clinical Development).
A replay of the prerecorded presentation will be available on the company’s Events and Presentations webpage starting at 2:00 PM ET on February 12, 2026, and will be archived for up to 30 days following the presentation date.